US firm Viatris has developed a new form of Viagra ... 50mg dose pouches comparable in cost to classic tablet versions. Interestingly, sildenafil was serendipitously found during an early '90s ...

Once regarded as a little blue miracle for sufferers of erectile dysfunction everywhere, Viagra completely transformed ... with aluminium pouches containing around 50mg doses being similarly ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

Now, Pfizer and the trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) rank among the organizations that have helped Trump raise a record-setting $150 million in pledges ...

After showing that Pfizer (NYSE:PFE) has halted its cooperation to develop giroctocogene fitelparvovec, an experimental gene therapy for hemophilia A in adults, Sangamo Therapeutics (NASDAQ ...

Investing.com -- Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their partnership to co-develop a gene therapy for hemophilia A (HemoA), sending ...

The end of the agreement delays Sangamo’s pathway to market, as Pfizer had been expected to submit data for potential regulatory approval of the therapy in early 2025. Pfizer stated the decision ...

After showing that Pfizer (NYSE:PFE) has halted its cooperation to develop giroctocogene fitelparvovec, an experimental gene therapy for hemophilia A in adults, Sangamo Therapeutics (NASDAQ:SGMO) ...

Shares of Sangamo Therapeutics slumped after the company filed to terminate its deal with pharmaceutical company Pfizer. The company's stock fell 55% to $1.02 in after-hours trading Monday.